Treating Multiple Myeloma in North Africa, the Middle East, and Europe
Emerging and Practical Concepts in Multiple Myeloma
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.
Date and Location
9–10 April 2021, Virtual Meeting
Faculty
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
Majed Alahmadi, MD
King Abdulaziz Medical City,
Kingdom of Saudi Arabia
Irene Ghobrial, MD
Dana-Farber Cancer Institute, USA
Mervat Mattar, MD
Cairo University, Egypt
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Mohamad Mohty MD
Saint-Antoine Hospital and Sorbonne University, Paris, France
Keith Stewart, MD
Princess Margaret Cancer Centre, Canada
|
Agenda |
This virtual program will take place over 2 days. Day 1: Minimal Residual Disease, Frontline Therapies, and the Role of Transplantation Day 2: Management of High-Risk, Relapsed, and Heavily Pretreated Multiple Myeloma, New and Future Therapies, and Patient Case Discussion |
Day 1: Friday, April 9, 2021
16.00 – 18.30 CET / 17.00 – 19.30 AST (UTC+3)
| KSA time (UTC+3) | Topic | Presenter |
| 17.00 – 17.15 | Welcome and Meeting Overview | Rafael Fonseca |
| 17.15 – 17.35 | Smoldering Multiple Myeloma • Diagnosis, criteria, and when and how to intervene |
Irene Ghobrial |
| 17.35 – 17.55 | Role of Minimal Residual Disease in Multiple Myeloma • Prognostic value, clinical relevance, and MRD-driven therapeutic guidance |
Majed Alahmadi |
| 17.55 – 18.15 | Frontline Therapy for Newly Diagnosed Transplant-Eligible Multiple Myeloma: The Role of Transplantation • Guidelines, induction therapies, and how and when to transplant |
Mervat Mattar |
| 18.15 – 18.35 | Optimal Use of Consolidation and Maintenance Therapy • Evolving insights in consolidation and maintenance treatment after transplant |
Mohamad Mohty |
| 18.35 – 18.50 | Break | |
| 18.50 – 19.15 | Frontline Therapy for Newly Diagnosed Transplant-Ineligible Patients • Criteria, guidelines, and treatment choices |
Keith Stewart |
| 19.15 – 19.30 | Session Close | Rafael Fonseca |
Day 2: Saturday, April 10, 2021
16.00 – 19.15 CET / 17.00 – 20.15 AST (UTC+3)
| KSA time (UTC+3) | Topic | Presenter |
| 17.00 – 17.10 | Session Open | Rafael Fonseca |
| 17.10 – 17.30 | Identification and Special Considerations for High-Risk Multiple Myeloma • Risk stratification, prognosis, and treatment choices |
María-Victoria Mateos |
| 17.30 – 17.55 | Management of Early Relapse of Multiple Myeloma • Definition, prognosis, and treatment choices |
Rafael Fonseca |
| 17.55 – 18.20 | Management of Heavily Pretreated Multiple Myeloma • Optimal use of treatment choices in relapsed/refractory multiple myeloma, excluding T-cell engagers |
Keith Stewart |
| 18.20 – 18.30 | Break | |
| 18.30 – 19.20 | New and Future Therapies for Multiple Myeloma • Latest trial updates, and upcoming and promising new strategies, including T-cell engagers |
Irene Ghobrial |
| 19.20 – 20.00 | Patient Case Discussion: Relapsed/Refractory Multiple Myeloma • Treatment challenges in relapsed/refractory MM in the region (10 min) • Cases from the region will be discussed with the faculty – “tumor board approach” (30 min) |
All faculty |
| 20.00 – 20.15 | Session Close | Rafael Fonseca |
